+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Europe Neurological Biomarkers Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product; Application; End User

  • PDF Icon

    Report

  • 144 Pages
  • August 2020
  • Region: Europe
  • The Insight Partners
  • ID: 5147187
UP TO OFF until Mar 31st 2024
The European neurological biomarkers market is expected to reach US$ 3,062.94 Mn in 2027 from US$ 1,221.15 Mn in 2019. The market is estimated to grow with a CAGR of 12.4% from 2020-2027.

The market is expected to witness a substantial growth due to driving factors such as rising prevalence of neurological disorders and progressive research in neurological biomarkers. However, the complications associated with the use of neurological biomarkers are expected to hinder the market growth. In addition, rising awareness regarding benefits of early diagnosis is expected to provide growth opportunities to the market players for developing new biomarkers whereas, the patient inclination toward personalized/precision medicine is expected to be a prevalent trend in the market.

Biomarkers are the molecules that indicate about the presence of a disease. The biomarkers of the neurological diseases were not that accessible in earlier days, however the advancements in the technology have enabled to track the health condition of the brain by measuring the biomarkers. This helps in the earlier detection of a disease, less invasive diagnostics and enables faster drug development and is expected to be the effective treatment.

Rapid developments in healthcare and drug discovery sector are leading to the introduction of new therapeutic solutions for the treatment of neurological diseases. Authorities such as World Health Organization, National Institute of Neurological Disorders and Stroke, and National Institutes of Health are taking constructive steps to encourage the research activities and find a remedy for neurological disease treatment.

Neurological diseases are commonly occurring diseases in Europe, and neurologists are focused toward management of these diseases in most European countries. The European Academy of Neurology (EAN) is conducting a research project to estimate the current situation regarding neurological diseases and the care of neurology patients in Europe
According to the European Academy of Neurology, the prevalence of neurological diseases in European Union is approximately 307,859,199. Furthermore, the data by Institute of Health Matrix and Evaluation states that more than half of the European population ranging up to 60% suffers from a neurological disease. The high prevalence of these diseases is expected to augment the growth of the market over the coming years.

The Burden of Stroke in Europe report conducted by King’s College London for the Stroke Alliance for Europe, the incidence of stroke is around 88,922 cases of stroke, which are 51.7 strokes per 100,000 inhabitants annually in Germany. The prevalence of stroke in Germany was around 526,774, accounting for 338.5 strokes per 100,000 inhabitants. The country also has a significant mortality rate of stroke, i.e. 75,861 deaths due to stroke per year. Furthermore, the increasing cases of brain tumour in the region are also primarily responsible for market growth. For instance, as per the data of 2019 Lancet Neurol; 18: 376–93, approximately 6,359 cases of brain and central nervous system (CNS) cancer were reported in the country in 2016.

Thus, increasing prevalence of neurological diseases is a major factor driving the growth of the Europe neurological biomarker market during the forecast period.

The COVID-19 pandemic effect on neurology patients is high in terms of fear, anxiety, and psychological distress. Among all European countries, Spain, Italy, Germany, France, and the UK are most affected due to the increasing number of coronavirus cases and deaths associated with it. As per the World meter, in UK, Spain, Italy, Germany, and France, the number of cases is 291,409; 289,787; 236,142; 186,795; 155,561; and 279,856 respective and number of deaths is high.

Based on product, in 2019, the genomic biomarkers segment held the largest share of the market and is expected to grow at the fastest CAGR during the forecast period. This segment is likely to witness a lucrative growth owing to increasing awareness among consumers regarding benefits of genetic medicines as well as technological advancements in the field of neurological biomarkers. In addition, the trend shift towards adoption of gene counseling and genetic analysis for diagnostic purposes is also likely to augment the growth of the segment. The genetic biomarkers are significant modalities that directs towards a more personalized approach of predispositions and medical analysis.

Some of the significant secondary sources for neurological biomarkers market included in the report are the World Health Organization (WHO), National Health Service (NHS), Biomarker Research and Imaging for Neuroscience (BRAIN), European Commission (EC), and others.

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Europe Neurological Biomarkers Market - By Product
1.3.2 Europe Neurological Biomarkers Market - By Application
1.3.3 Europe Neurological Biomarkers Market - By End User
1.3.4 Europe Neurological Biomarkers Market - By Country
2. Europe Neurological Biomarkers Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Neurological Biomarkers Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Neurological Biomarkers Market - Europe PEST Analysis
4.3 Expert Opinion
5. Europe Neurological Biomarkers Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rising Prevalence of Neurological Disorders
5.1.2 Progressive Research in Neurological Biomarkers
5.2 Key Market Restraints
5.2.1 Complications Associated with the Use of Neurological Biomarkers
5.3 Market Opportunities
5.3.1 Rising Awareness Regarding Benefits of Early Diagnosis
5.4 Future Trends
5.4.1 Patient Inclination Toward Personalized/Precision Medicine
5.5 Impact analysis
6. Neurological Biomarkers Market - Europe Analysis
6.1 Europe Neurological Biomarkers Market Revenue Forecasts and Analysis
7. Europe Neurological Biomarkers Market Analysis And Forecasts To 2027 - By Product
7.1 Overview
7.2 Europe Neurological Biomarkers market, By Product 2019 & 2027 (%)
7.2.1 Europe Neurological Biomarkers Market Revenue and Forecasts to 2027, By Product (US$ Mn)
7.3 Proteomics Biomarker
7.3.1 Overview
7.3.2 Europe Proteomics Biomarker Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Genomics Biomarker
7.4.1 Overview
7.4.2 Europe Genomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Metabolomics Biomarker
7.5.1 Overview
7.5.2 Europe Metabolomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Imaging Biomarker
7.6.1 Overview
7.6.2 Europe Imaging Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.7 Others
7.7.1 Overview
7.7.2 Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
8. Europe Neurological Biomarkers Market Analysis - By Application
8.1 Overview
8.2 Europe Neurological Biomarkers Market, By Application 2019-2027 (%)
8.2.1 Europe Neurological Biomarkers Market Revenue and Forecasts to 2027, By Application (US$ Mn)
8.3 Alzheimer’s Disease
8.3.1 Overview
8.3.2 Europe Alzheimer’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Parkinson’s Disease
8.4.1 Overview
8.4.2 Europe Parkinson’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Schizophrenia
8.5.1 Overview
8.5.2 Europe Schizophrenia Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Huntington's Disease
8.6.1 Overview
8.6.2 Europe Huntington's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Spinal Muscular Atrophy
8.7.1 Overview
8.7.2 Europe Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Others
8.8.1 Overview
8.8.2 Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
9. Europe Neurological Biomarkers Market Analysis - By End User
9.1 Overview
9.2 Europe Neurological Biomarkers Market, By End User 2019-2027 (%)
9.2.1 Europe Neurological Biomarkers Market Revenue and Forecasts to 2027, By End User (US$ Mn)
9.3 Pharmaceutical and Biotechnology Companies
9.3.1 Overview
9.3.2 Europe Pharmaceutical and Biotechnology Companies Market Revenue and Forecasts to 2027 (US$ Mn)
9.4 Clinical Diagnostics
9.4.1 Overview
9.4.2 Europe Clinical Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Research Organizations
9.5.1 Overview
9.5.2 Europe Research Organizations Market Revenue and Forecasts to 2027 (US$ Mn)
10. Neurological Biomarkers Market Revenue and Forecasts To 2027 - Geographical Analysis
10.1 Europe: Neurological Biomarker Market
10.1.1 Overview
10.1.2 Europe: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
10.1.3 Europe: Neurological Biomarker Market, by Product, 2018-2027 (USD Million)
10.1.4 Europe: Neurological Biomarker Market, by Application, 2018-2027 (USD Million)
10.1.5 Europe: Neurological Biomarker Market, by End-User, 2018-2027 (USD Million)
10.1.6 Europe: Neurological Biomarker Market, by Country, 2019& 2027 (%)
10.1.7 Germany: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
10.1.7.1 Germany: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
10.1.7.2 Germany: Neurological Biomarker Market, by Product, 2018-2027 (USD Million)
10.1.7.3 Germany: Neurological Biomarker Market, by Application, 2018-2027 (USD Million)
10.1.7.4 Germany: Neurological Biomarker Market, by End-User, 2018-2027 (USD Million)
10.1.8 United Kingdom: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
10.1.8.1 United Kingdom: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
10.1.8.2 United Kingdom: Neurological Biomarker Market, by Product, 2018-2027 (USD Million)
10.1.8.3 United Kingdom: Neurological Biomarker Market, by Application, 2018-2027 (USD Million)
10.1.8.4 United Kingdom: Neurological Biomarker Market, by End-User, 2018-2027 (USD Million)
10.1.9 France: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
10.1.9.1 France: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
10.1.9.2 France: Neurological Biomarker Market, by Product, 2018-2027 (USD Million)
10.1.9.3 France: Neurological Biomarker Market, by Application, 2018-2027 (USD Million)
10.1.9.4 France: Neurological Biomarker Market, by End-User, 2018-2027 (USD Million)
10.1.10 Spain: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
10.1.10.1 Spain: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
10.1.10.2 Spain: Neurological Biomarker Market, by Product, 2018-2027 (USD Million)
10.1.10.3 Spain: Neurological Biomarker Market, by Application, 2018-2027 (USD Million)
10.1.10.4 Spain: Neurological Biomarker Market, by End-User, 2018-2027 (USD Million)
10.1.11 Italy: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
10.1.11.1 Italy: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
10.1.11.2 Italy: Neurological Biomarker Market, by Product, 2018-2027 (USD Million)
10.1.11.3 Italy: Neurological Biomarker Market, by Application, 2018-2027 (USD Million)
10.1.11.4 Italy: Neurological Biomarker Market, by End-User, 2018-2027 (USD Million)
11. Impact of COVID-19 Pandemic on Europe Neurological Biomarkers Market
11.1 Europe: Impact Assessment Of COVID-19 Pandemic
12. Company Profiles
12.1 Myriad Genetics, Inc.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 QIAGEN
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 MERCK KGaA
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Thermo Fisher Scientific Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Abbott
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
13. Appendix
13.1 About the Publisher
13.2 Word Index
List of Tables
Table 1. Europe Neurological Biomarkers Market Revenue and Forecasts To 2027, By Product (US$ Mn)
Table 2. Europe Neurological Biomarkers Market Revenue and Forecasts To 2027, By Application (US$ Mn)
Table 3. Europe Neurological Biomarkers Market Revenue and Forecasts To 2027, By End User (US$ Mn)
Table 4. Europe Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 5. Europe Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 6. Europe Neurological Biomarker Market, by End-User– Revenue and Forecast to 2027 (USD Million)
Table 7. US Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 8. US Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 9. US Neurological Biomarker Market, by End-User– Revenue and Forecast to 2027 (USD Million)
Table 10. Canada Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 11. Canada Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 12. Canada Neurological Biomarker Market, by End-User– Revenue and Forecast to 2027 (USD Million)
Table 13. Mexico Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 14. Mexico Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 15. Mexico Neurological Biomarker Market, by End-User– Revenue and Forecast to 2027 (USD Million)
Table 16. List of Abbreviation
List of Figures
Figure 1. Neurological Biomarkers Market Segmentation
Figure 2. Europe Neurological Biomarkers Market Overview
Figure 3. Genomic Biomarkers Segment Held Largest Share of Neurological Biomarker Market
Figure 4. US is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. Europe Neurological Biomarkers Market - Leading Country Markets (US$ Mn)
Figure 6. Neurological Biomarkers Market - Europe PEST Analysis
Figure 7. Neurological Biomarkers Market Impact Analysis Of Driver And Restraints
Figure 8. Europe Neurological Biomarkers market – Revenue Forecasts and Analysis – 2019- 2027
Figure 9. Europe Neurological Biomarkers market, By Product 2019 & 2027 (%)
Figure 10. Europe Proteomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 11. Europe Genomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. Europe Metabolomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. Europe Imaging Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. Europe Neurological Biomarkers Market, by Application 2019 & 2027 (%)
Figure 16. Europe Alzheimer’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 17. Europe Parkinson’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. Europe Schizophrenia Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. Europe Huntington's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. Europe Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. Europe Neurological Biomarkers Market, by End User 2019 & 2027 (%)
Figure 23. Europe Pharmaceutical and Biotechnology Companies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. Europe Clinical Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Europe Research Organizations Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. Europe: Neurological Biomarker Market, by Key Country – Revenue (2019) (USD Million)
Figure 27. Europe Neurological Biomarker Market Revenue and Forecast to 2027 (USD Million)
Figure 28. Europe: Neurological Biomarker Market, by Country, 2019 & 2027 (%)
Figure 29. US: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
Figure 30. Canada: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
Figure 31. Mexico: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
Figure 32. Impact of COVID-19 Pandemic in Europen Country Markets

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Thermo Fisher Scientific, Inc
  • Myriad Genetics
  • QIAGEN
  • Abbott
  • Merck KGaA